- Home
- VRTX vs STX Comparison
VRTX vs STX Comparison
Compare VRTX & STX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRTX | STX |
|---|---|---|
| Founded | 1989 | 1978 |
| Country | United States | Singapore |
| Employees | 6400 | N/A |
| Industry | EDP Services | Electronic Components |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6B | 157.1B |
| IPO Year | 2006 | 2002 |
Fundamental Metrics
Financial Performance| Metric | VRTX | STX |
|---|---|---|
| Price | $526.14 | $631.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 26 |
| Target Price | $571.46 | ★ $1,138.33 |
| AVG Volume (30 Days) | 1.1M | ★ 3.9M |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 0.46% |
| EPS Growth | ★ 836.54 | 105.32 |
| EPS | 8.33 | ★ 13.90 |
| Revenue | $2,488,652,000.00 | ★ $7,384,000,000.00 |
| Revenue This Year | $10.54 | $55.46 |
| Revenue Next Year | $9.74 | $34.80 |
| P/E Ratio | $64.00 | ★ $46.09 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $403.16 | $217.67 |
| 52 Week High | $560.25 | $1,145.00 |
Technical Indicators
Market Signals| Indicator | VRTX | STX |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 30.47 |
| Support Level | $493.75 | $364.17 |
| Resistance Level | $531.78 | $939.07 |
| Average True Range (ATR) | 12.57 | 37.31 |
| MACD | 3.53 | -14.38 |
| Stochastic Oscillator | 77.83 | 4.34 |
Price Performance
Historical ComparisonAbout VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
About STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.